Testosterone Replacement Therapy

Home » Testosterone Replacement Therapy

Testosterone Replacement Therapy Side Effects Attorney

Testosterone Replacement Therapy (TRT) or “Low-T” Treatment Products 

Attorneys at The Olinde Firm are investigating claims on behalf of clients who used Testosterone Replacement Therapy (TRT) or “Low-T” products AndroGel, AndroDerm, Axiron, or Testim and suffered serious health problems, including:

  • Heart Attack
  • Stroke
  • Pulmonary Embolism
  • Deep Vein Thrombosis (DVT)
  • Blood Clots
  • Death

Testosterone treatments are approved by the FDA to treat those with a diagnosed medical condition known as hypogonadism in which the body produces very little or no testosterone. Men typically experience some level of decline in testosterone production as a natural part of the aging process. However, drug manufacturers have sought to capitalize on this natural testosterone decline by aggressively marketing testosterone treatments or “Low-T” drugs to the public as a treatment to reverse the natural aging process. Drug companies such as AbbVie and Eli Lilly engaged in broad information campaigns telling people “Do you sometimes feel a little tired? Do you have less energy then you used to? Then talk to your doctor about Low T” as a way to push the public into testosterone therapy products. As a result, testosterone therapy treatments have more than doubled in the last ten years, bringing in over $3 billion in 2013.



Many doctors and patients feel misled by the manufacturers of testosterone products about the appropriate use and potential risks and side effects associated with testosterone therapy. Lawyers around the country have filed lawsuits against testosterone therapy manufacturers alleging a failure to properly warn physicians and patients regarding the increased risk of heart attack and stroke associated with use of the drugs.

UPDATE (June 2014):

The U.S. Judicial Panel on Multidistrict Litigation (JPML) has ordered that lawsuits filed around the country against manufacturers of testosterone replacement products will be centralized in a Multi-District Litigation (MDL) in the Northern District of Illinois before the Honorable Matthew F. Kennelly.

UPDATE (March 2015):

U.S. Food and Drug Administration (FDA) issues a Drug Safety Communication cautioning about the use of Testosterone Products for the natural decline in testosterone due to aging and requiring manufacturers to change their warning labels to inform users of the possible increased risk of Heart Attack and Stroke associated with use of testosterone products.


  • This field is for validation purposes and should be left unchanged.

If you or a loved one took testosterone products and suffered from a heart attack, stroke, blood clot or other significant health problem after taking the drug, contact our office to speak with an attorney about your potential recovery of damages.

New Orleans

Of Counsel at Huber, Thomas & Marcelle
1100 Poydras Street, Suite 2200
New Orleans, LA 70163

Phone: (504) 587-1440
Toll Free:1-800-587-1889

North Shore

Main Office and Mailing Address
2 Sanctuary Boulevard
Suite 205
Mandeville, LA 70471

Phone: (985) 605-0262
Toll Free: 1-800-587-1889

New Orleans East

New Orleans East Office
8816 Chef Menteur Highway
Suite B
New Orleans, LA 70127

Phone: (504) 587-1440
Toll Free: 1-800-587-1889

Free Case Evaluation

Copyright © 2019 The Olinde Firm - New Orleans Attorneys. All rights reserved. Disclaimer The information contained in this website may be considered advertising under the Rules of the Supreme Judicial Court of Louisiana and is for general information purposes only. Nothing contained within this or associated pages, documents, emails, or other communications should be taken as legal advice for any individual case or situation. The information on this website is not intended to create, and communications exchanged in connection with this website are not intended to create or constitute an attorney-client relationship. Although all communications are considered confidential, we do not accept representation of clients until such time as we enter into a written agreement for such representation.